Rising medicinal use On one July, 2023, the Therapeutic Goods Administration amended its scheduling of copyright substances to enable the prescription of psilocybin to be used in copyright assisted psychotherapy for treatment method-resistant melancholy. Trials as to their usefulness and safety in treating different psychiatric ailments are ongoin